(Q42607166)

English

Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study

scientific article published on July 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 November 2017

Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study (English)

1 reference

Europe PubMed Central

3 November 2017

multicenter clinical trial

0 references

0 references

0 references

author name string

Christian Brambilla

1

1 reference

Europe PubMed Central

3 November 2017

Vincent Le Gros

2

1 reference

Europe PubMed Central

3 November 2017

Isabelle Bourdeix

3

1 reference

Europe PubMed Central

3 November 2017

Efficacy of Foradil in Asthma (EFORA) French Study Group

4

1 reference

Europe PubMed Central

3 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 July 2003

1 reference

Europe PubMed Central

3 November 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

3 November 2017

25

1 reference

Europe PubMed Central

3 November 2017

7

1 reference

Europe PubMed Central

3 November 2017

2022-2036

1 reference

Europe PubMed Central

3 November 2017

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Beta-agonist intrinsic efficacy: measurement and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980202-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)80202-3

1 reference

Europe PubMed Central

3 November 2017

1 reference

Europe PubMed Central

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42607166&oldid=1962762950"